Author:
Li Zhenyun,Gao Yuan,Zhang Bianfang,Dong Wei,Xi Yuling,Li Yan,Cui Junwei
Abstract
AbstractMacrophages act as the first immune defense line of the host against Mycobacterium tuberculosis (Mtb). A previous study showed that circRNA_SLC8A1 was significantly upregulated in Mtb-infected macrophages, but its regulatory mechanism in anti-tuberculosis infection is unclear. Therefore, this study aimed to investigate the role of circRNA_SLC8A1 in the anti-tuberculosis activity of macrophages. We showed that circRNA_SLC8A1 was upregulated in tuberculosis patients. Moreover, the binding sites of miR-20b-5p on circRNA_SLC8A1 and Sequestosome 1 (SQSTM1/p62) mRNA were predicted by StarBase and verified by the double luciferase reporter gene assay. Next, we found that miR-20b-5p expression was decreased, while SQSTM1 protein expression was increased in a time- and dose-dependent manner in the human macrophage U937 in response to Mtb infection. Furthermore, circRNA_SLC8A1 overexpression vector (circRNA_SLC8A1) or shRNA (sh-circRNA_SLC8A1) and/or miR-20b-5p mimic or inhibitor and/or SQSTM1 overexpression vector (SQSTM1) or small interfering RNA (si-SQSTM1) or its corresponding control were transfected into Mtb-infected macrophages. Results showed that overexpression of circRNA_SLC8A1 or miR-20b-5p inhibitor promoted the secretion of pro-inflammatory factors IL-1β, IL-6, and TNF-α, increased Nitric Oxide (NO) content and inducible nitric oxide synthase (iNOS) expression, inhibited Reactive oxygen species (ROS) production. Cleaved-caspase-3 protein expression, and cell apoptosis, and promoted Mtb survival. Silencing SQSTM1 inhibited secretion of pro-inflammatory factors and activation of the NF-κB pathway. Overexpression of miR‐20b‐5p blocked the promoting of circ‐SLC8A1 on SQSTM1 protein expression. In summary, circRNA_SLC8A1 sponged miR‐20b‐5p to upregulate SQSTM1/p62 expression and promoted Mtb survival in macrophages through the NF-κB signaling pathway.
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Shaku, M. T. & Bishai, W. R. Mycobacterium tuberculosis: A pathogen that can hold its breath a long time. Am. J. Respir. Crit. Care Med. 206, 10–12 (2022).
2. Dale, K. D., Schwalb, A. & Houben, R. Estimating annual risk of infection with Mycobacterium tuberculosis. Lancet Infect. Dis. 22, 1275–1276 (2022).
3. Li, Q. et al. Transition between Mycobacterium tuberculosis and nontuberculous mycobacteria in recurrent tuberculosis patients. Eur. J. Clin. Microbiol. Infect. Dis. 41, 1127–1132 (2022).
4. Rahlwes, K. C., Dias, B. R. S., Campos, P. C., Alvarez-Arguedas, S. & Shiloh, M. U. Pathogenicity and virulence of Mycobacterium tuberculosis. Virulence 14, 2150449 (2023).
5. Bouzeyen, R. & Javid, B. Therapeutic vaccines for Tuberculosis: An overview. Front. Immunol. 13, 878471 (2022).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献